Q1 FY27 saw 15.8% revenue and 17.0% PAT growth year-over-year, with improved margins and strong performance across segments. The company entered the Top 50 Pharma Companies in India and received three industry awards, while maintaining robust financial health and pursuing strategic expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.